查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1579064

葡萄膜炎治疗药物市场：按治疗类型、疾病类型、原因、分销管道 - 全球预测 2025-2030

Uveitis Treatment Market by Treatment Type (Analgesics, Antibiotics, Antifungal), Disease Type (Anterior Uveitis, Intermediate Uveitis, Panuveitis), Cause, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年葡萄膜炎治疗药物市值为7.2465亿美元，预计到2024年将达到7.8324亿美元，复合年增长率为8.48%，到2030年将达到12.8123亿美元。

葡萄膜炎药物是指旨在控制葡萄膜炎的治疗策略。葡萄膜炎是眼睛葡萄膜的发炎，如果不治疗可能导致视力丧失。此类治疗包括皮质类固醇、免疫抑制剂、生物製药和手术介入。这些治疗对于保护视力、缓解疼痛和解决感染疾病或自体免疫疾病等根本原因至关重要。主要应用包括前、中、后和全葡萄膜炎管理，最终用户是医院、眼科诊所和专业眼科护理中心。

主要市场统计
基准年[2023] 7.2465亿美元
预测年份 [2024] 7.8324 亿美元
预测年份 [2030] 1,281.23 百万美元
复合年增长率（%） 8.48%

由于人们认识的提高、生物製药开发的进步以及全球自体免疫疾病盛行率的上升，葡萄膜炎治疗市场正在不断增长。诊断方法的改进和对病理学的更深入了解正在进一步支持市场扩张。生物目标和新型药物输送系统的开发存在重大商机，例如有望提高疗效和患者依从性的缓释性眼部植入。鼓励公司投资研发，专注于个人化医疗方法，并利用伙伴关係关係进行创新技术整合。

然而，不断上涨的治疗成本、潜在的药物副作用以及低收入地区缺乏药物供应给市场成长带来了挑战。此外，监管障碍和新治疗方法的缓慢采用也构成了重大挑战。解决这些限制因素需要增加对负担得起的治疗的投资，并透过策略伙伴关係和政府支持扩大可及性。

新的研究领域包括基因治疗和生活方式改善干预措施，预计将提供新的治疗途径。在不断创新和新进入者的推动下，市场本质上是充满活力和竞争的。旨在实现成长的公司应专注于透过资料分析对患者行为进行竞争考察洞察，并保持以患者为中心的方法来识别未满足的需求并获得竞争优势。

市场动态：快速发展的葡萄膜炎治疗市场的关键市场洞察

葡萄膜炎药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 人口老化加剧和慢性眼部疾病盛行率增加
    • 葡萄膜炎影像诊断技术进展
    • 药物传输方法的技术改进
  • 市场限制因素
    • 治疗时间长、治疗费用大
  • 市场机会
    • 持续研究和开发创新治疗方法
    • 远端医疗和远距患者监护的出现
  • 市场挑战
    • 与使用全身免疫抑制剂相关的副作用

波特的五力：驾驭葡萄膜炎药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解葡萄膜炎治疗药物市场的外部影响

外部宏观环境因素在影响葡萄膜炎治疗药物市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解葡萄膜炎治疗药物市场的竞争状况

对葡萄膜炎治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵葡萄膜炎治疗市场供应商的绩效评估

FPNV 定位矩阵是评估葡萄膜炎治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘葡萄膜炎治疗药物市场的成功之路

对于想要加强在全球市场的影响力的公司来说，葡萄膜炎治疗药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口老化加剧和慢性眼科疾病增加
      • 葡萄膜炎影像诊断技术进展
      • 药物传输方法的技术改进
    • 抑制因素
      • 治疗时间长、治疗费用大
    • 机会
      • 持续研究并开发创新治疗方法
      • 远端医疗和远距患者监护的出现
    • 任务
      • 与使用全身免疫抑制剂相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章葡萄膜炎治疗药物市场（依治疗类型）

  • 止痛药
  • 抗生素
  • 抗真菌剂
  • 抗病毒药物
  • 皮质类固醇
  • 睫状肌麻痹药
  • 免疫抑制剂
  • 单株抗体

第七章葡萄膜炎治疗药物市场：依疾病类型

  • 前葡萄膜炎
  • 中间葡萄膜炎
  • 葡萄膜炎
  • 后葡萄膜炎

第八章葡萄膜炎治疗药物市场（按原因）

  • 传染性的
  • 非传染性的

第九章葡萄膜炎治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第十章 北美和南美葡萄膜炎治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区葡萄膜炎治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲葡萄膜炎治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Accutome, Inc.
  • Ajanta Pharma Ltd.
  • Alcon Vision LLC
  • Allergan PLC
  • Amorphex Therapeutics Holdings, Inc.
  • Appasamy Ocular Device Pvt Ltd.
  • Astellas Pharma Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Cipla Ltd.
  • Entod Pharmaceuticals Ltd.
  • EyePoint Pharmaceuticals, Inc.
  • Fera Pharmaceuticals
  • His Eyeness Ophthalmics Pvt Ltd.
  • Intas Pharmaceuticals Ltd.
  • JB Chemicals And Pharmaceuticals Ltd.
  • Kubota Vision Inc.
  • Merck & Co. Inc.
  • Micro Labs Ltd.
  • Nidek Co Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sunways India Pvt Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-742BD5184C9B

The Uveitis Treatment Market was valued at USD 724.65 million in 2023, expected to reach USD 783.24 million in 2024, and is projected to grow at a CAGR of 8.48%, to USD 1,281.23 million by 2030.

Uveitis treatment refers to therapeutic strategies aimed at managing uveitis, an inflammation of the uvea in the eye that can result in vision loss if untreated. The scope of such treatments encompasses corticosteroids, immunosuppressants, biologics, and surgical interventions. These treatments are crucial for preserving vision, alleviating pain, and addressing underlying causes such as infection or autoimmune diseases. Major applications include management of anterior, intermediate, posterior, and panuveitis, with end-users being hospitals, ophthalmic clinics, and specialty eye care centers.

KEY MARKET STATISTICS
Base Year [2023] USD 724.65 million
Estimated Year [2024] USD 783.24 million
Forecast Year [2030] USD 1,281.23 million
CAGR (%) 8.48%

The uveitis treatment market is experiencing growth due to increasing awareness, advancements in biologic drug development, and a rising prevalence of autoimmune disorders worldwide. Improved diagnostics and a better understanding of pathophysiological aspects are further driving market expansion. Significant opportunities lie in the development of targeted biologics and novel drug delivery systems, such as sustained-release ocular implants, which promise enhanced efficacy and patient compliance. Companies are advised to invest in R&D, focusing on personalized medicine approaches and leveraging partnerships for innovative technology integration.

However, market growth is challenged by the high cost of treatment, potential side effects of drugs, and a lack of availability in low-income regions. Additionally, regulatory hurdles and the slow adoption of novel therapies pose significant challenges. Addressing these limitations involves increasing investment in affordable therapies and expanding access through strategic collaborations and governmental support.

Emerging research areas include the investigation of gene therapy and lifestyle modification interventions, which show promise in offering new pathways for treatment. The market is inherently dynamic and competitive, driven by ongoing innovation and the entry of new market players. Companies poised for growth should focus on harnessing data analytics for patient behavioral insights and maintain a patient-centric approach in their strategies to tap into unmet needs and gain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Uveitis Treatment Market

The Uveitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population and increasing prevalence of chronic eye disorders
    • Advancement in diagnostic techniques for imaging uveitis
    • Technical improvement in drug delivery methods
  • Market Restraints
    • Long-term treatment and huge treatment costs
  • Market Opportunities
    • Ongoing research and development for innovative treatment therapies
    • Emergence of telemedicine and remote monitoring of patients
  • Market Challenges
    • Side-effects associated with the usage of systemic immunosuppressive medications

Porter's Five Forces: A Strategic Tool for Navigating the Uveitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Uveitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Uveitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Uveitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Uveitis Treatment Market

A detailed market share analysis in the Uveitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Uveitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Uveitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Uveitis Treatment Market

A strategic analysis of the Uveitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Uveitis Treatment Market, highlighting leading vendors and their innovative profiles. These include Accutome, Inc., Ajanta Pharma Ltd., Alcon Vision LLC, Allergan PLC, Amorphex Therapeutics Holdings, Inc., Appasamy Ocular Device Pvt Ltd., Astellas Pharma Inc., Bausch & Lomb Incorporated, Bayer AG, Cipla Ltd., Entod Pharmaceuticals Ltd., EyePoint Pharmaceuticals, Inc., Fera Pharmaceuticals, His Eyeness Ophthalmics Pvt Ltd., Intas Pharmaceuticals Ltd., J B Chemicals And Pharmaceuticals Ltd., Kubota Vision Inc., Merck & Co. Inc., Micro Labs Ltd., Nidek Co Ltd., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Sunways India Pvt Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Uveitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Analgesics, Antibiotics, Antifungal, Antivirals, Corticosteroids, Cycloplegic Agents, Immunosuppressant, and Monoclonal Antibodies.
  • Based on Disease Type, market is studied across Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Posterior Uveitis.
  • Based on Cause, market is studied across Infectious and Noninfectious.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and increasing prevalence of chronic eye disorders
      • 5.1.1.2. Advancement in diagnostic techniques for imaging uveitis
      • 5.1.1.3. Technical improvement in drug delivery methods
    • 5.1.2. Restraints
      • 5.1.2.1. Long-term treatment and huge treatment costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for innovative treatment therapies
      • 5.1.3.2. Emergence of telemedicine and remote monitoring of patients
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects associated with the usage of systemic immunosuppressive medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Uveitis Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Analgesics
  • 6.3. Antibiotics
  • 6.4. Antifungal
  • 6.5. Antivirals
  • 6.6. Corticosteroids
  • 6.7. Cycloplegic Agents
  • 6.8. Immunosuppressant
  • 6.9. Monoclonal Antibodies

7. Uveitis Treatment Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Anterior Uveitis
  • 7.3. Intermediate Uveitis
  • 7.4. Panuveitis
  • 7.5. Posterior Uveitis

8. Uveitis Treatment Market, by Cause

  • 8.1. Introduction
  • 8.2. Infectious
  • 8.3. Noninfectious

9. Uveitis Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Uveitis Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Uveitis Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Uveitis Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accutome, Inc.
  • 2. Ajanta Pharma Ltd.
  • 3. Alcon Vision LLC
  • 4. Allergan PLC
  • 5. Amorphex Therapeutics Holdings, Inc.
  • 6. Appasamy Ocular Device Pvt Ltd.
  • 7. Astellas Pharma Inc.
  • 8. Bausch & Lomb Incorporated
  • 9. Bayer AG
  • 10. Cipla Ltd.
  • 11. Entod Pharmaceuticals Ltd.
  • 12. EyePoint Pharmaceuticals, Inc.
  • 13. Fera Pharmaceuticals
  • 14. His Eyeness Ophthalmics Pvt Ltd.
  • 15. Intas Pharmaceuticals Ltd.
  • 16. J B Chemicals And Pharmaceuticals Ltd.
  • 17. Kubota Vision Inc.
  • 18. Merck & Co. Inc.
  • 19. Micro Labs Ltd.
  • 20. Nidek Co Ltd.
  • 21. Novartis AG
  • 22. Pfizer Inc.
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Sunways India Pvt Ltd.
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. UVEITIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. UVEITIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL UVEITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UVEITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. UVEITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. UVEITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL UVEITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. UVEITIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANTIFUNGAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CYCLOPLEGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ANTERIOR UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY INTERMEDIATE UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY PANUVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY POSTERIOR UVEITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY INFECTIOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY NONINFECTIOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL UVEITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES UVEITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM UVEITIS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM UVEITIS TREATMENT MARKET SIZE, BY CAUSE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. UVEITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. UVEITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023